1,924
Participants
Start Date
May 31, 2016
Primary Completion Date
March 3, 2021
Study Completion Date
March 3, 2021
VRC01
Administered by IV infusion; total dose will vary based on participant's weight
Placebo for VRC01
Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
The Aurum Institute Tembisa Clinical Research Centre CRS, Johannesburg
Soweto HVTN CRS, Johannesburg
Ward 21 CRS, Johannesburg
Wits Reproductive Health and HIV Institute CRS (WRHI CRS), Johannesburg
Aurum Institute Klerksdorp CRS, Klerksdorp
Botha's Hill CRS, Durban
CAPRISA eThekwini CRS, Durban
Vulindlela CRS, Durban
Chatsworth CRS, Chatsworth
Groote Schuur HIV CRS, Cape Town
Kisumu Crs, Kisumu
Gaborone CRS, Gaborone
Blantyre CRS, Blantyre
Malawi CRS, Lilongwe
Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS, Maputo
National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS, Mbeya
Seke South CRS, Chitungwiza
Milton Park CRS, Harare
Spilhaus CRS, Harare
Synexus Stanza Clinical Research Centre CRS, Pretoria
Rustenburg CRS, Rustenburg
National Institute of Allergy and Infectious Diseases (NIAID)
NIH